- Home
- BVN vs MRUS Comparison
BVN vs MRUS Comparison
Compare BVN & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BVN
- MRUS
- Stock Information
- Founded
- BVN 1953
- MRUS 2003
- Country
- BVN Peru
- MRUS Netherlands
- Employees
- BVN N/A
- MRUS N/A
- Industry
- BVN Metal Mining
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- BVN Basic Materials
- MRUS Health Care
- Exchange
- BVN Nasdaq
- MRUS Nasdaq
- Market Cap
- BVN 3.1B
- MRUS 3.3B
- IPO Year
- BVN 1996
- MRUS 2016
- Fundamental
- Price
- BVN $15.50
- MRUS $47.29
- Analyst Decision
- BVN Buy
- MRUS Strong Buy
- Analyst Count
- BVN 2
- MRUS 13
- Target Price
- BVN $16.50
- MRUS $86.85
- AVG Volume (30 Days)
- BVN 1.1M
- MRUS 642.4K
- Earning Date
- BVN 04-28-2025
- MRUS 05-07-2025
- Dividend Yield
- BVN 0.47%
- MRUS N/A
- EPS Growth
- BVN 1928.16
- MRUS N/A
- EPS
- BVN 1.59
- MRUS N/A
- Revenue
- BVN $1,154,605,000.00
- MRUS $36,133,000.00
- Revenue This Year
- BVN N/A
- MRUS $37.72
- Revenue Next Year
- BVN N/A
- MRUS $48.47
- P/E Ratio
- BVN $9.68
- MRUS N/A
- Revenue Growth
- BVN 40.15
- MRUS N/A
- 52 Week Low
- BVN $11.50
- MRUS $37.77
- 52 Week High
- BVN $18.84
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- BVN 75.03
- MRUS 60.80
- Support Level
- BVN $15.04
- MRUS $46.00
- Resistance Level
- BVN $15.91
- MRUS $48.78
- Average True Range (ATR)
- BVN 0.49
- MRUS 2.10
- MACD
- BVN 0.17
- MRUS -0.03
- Stochastic Oscillator
- BVN 97.61
- MRUS 79.78
About BVN Buenaventura Mining Company Inc.
Compania de Minas Buenaventura SAA is a Peruvian precious metals-producing company with experience in mine exploration, development, construction, and operation.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only one reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.